Product image of Ondansetron Noridem (Ondansetron) supplied by GNH India

Ondansetron Noridem

Active Ingredient:
Ondansetron
Origin:
EU

Ondansetron Noridem (Ondansetron)

Ondansetron, the active ingredient in Ondansetron Noridem, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult patients.

GNH India supplies Ondansetron Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The product conforms to EU market standards and is manufactured under strict quality controls. It is available for global distribution with appropriate regulatory documentation.

Manufacturer / TM Owner

Noridem Enterprises Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ondansetron acts on the 5‑HT3 receptor pathway to control nausea and vomiting.
  • Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy.
  • Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting caused by radiation treatment.
  • Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures.

How It Works

  • Ondansetron selectively antagonizes peripheral and central 5‑HT3 receptors, blocking serotonin-mediated signaling that triggers the vomiting reflex. By inhibiting these receptors in the chemoreceptor trigger zone and gastrointestinal tract, it diminishes the afferent signals that initiate nausea and emesis, providing antiemetic protection during chemotherapy, radiotherapy, and postoperative periods.

Side Effects

Common Side Effects

  • Headache: mild to moderate pain often reported after administration.
  • Constipation: reduced bowel motility leading to hard stools.
  • Dizziness: transient sensation of light‑headedness.
  • Fatigue: feeling of tiredness without exertion.
  • Injection site reactions: pain, erythema, or swelling at the site.
  • Diarrhoea: loose stools occurring shortly after dosing.

Serious or Rare Side Effects

  • QT interval prolongation: may predispose to cardiac arrhythmias.
  • Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and respiratory distress.
  • Serotonin syndrome: rare but possible when combined with other serotonergic agents.
  • Cardiac arrhythmia: irregular heartbeat requiring medical attention.
  • Hepatic dysfunction: abnormal liver enzymes in susceptible individuals.

Precautions & Warnings

  • Ondansetron should be used with caution in patients with specific risk factors.
  • Assess cardiac history: evaluate for QT‑prolongation risk before initiation.
  • Monitor electrolytes: correct hypokalaemia, hypomagnesaemia, or hypocalcaemia.
  • Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
  • Use cautiously in hepatic impairment: dose adjustment may be required.
  • Pregnancy considerations: safety not established; weigh benefits against potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ondansetron may interact with several medications.

Major Interactions (Avoid)

  • Other QT‑prolonging drugs (e.g., quinidine, haloperidol).
  • Apomorphine: concurrent use can cause severe hypotension.
  • Serotonergic agents (SSRIs, SNRIs, MAO inhibitors): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • Cimetidine: may increase ondansetron plasma levels.
  • Erythromycin: potential for elevated concentrations.
  • Dexamethasone: may enhance antiemetic effect, monitor response.
  • Aprepitant: combined antiemetic therapy may require dose adjustment.

Frequently Asked Questions

Ondansetron Noridem is an injectable antiemetic used to prevent and treat nausea and vomiting that result from chemotherapy, radiotherapy, and postoperative recovery. It works by blocking serotonin receptors that trigger the vomiting reflex.

Ondansetron selectively blocks peripheral and central 5‑HT3 receptors, preventing serotonin from activating the chemoreceptor trigger zone and gastrointestinal vagal afferents. This inhibition reduces the neural signals that cause nausea and vomiting.

The dose of ondansetron is determined by the prescribing clinician based on the patient’s condition, treatment protocol, and route of administration. Healthcare providers set the appropriate amount and schedule for each individual case.

Safety data for ondansetron during pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant, and decisions are made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, offering rapid and specific control of serotonin‑mediated nausea. Compared with dopamine antagonists such as metoclopramide, ondansetron has a lower risk of extrapyramidal side effects but may require cardiac monitoring for QT prolongation.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken vigorously. Once removed from refrigeration, use within the time frame specified by the manufacturer.

Ondansetron Noridem is given by intramuscular (IM) or intravenous (IV) injection. The route, volume, and rate of infusion are selected by the healthcare professional according to the clinical situation and patient needs.

Serious risks include QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for cardiac symptoms and signs of hypersensitivity.

Ondansetron is contraindicated in individuals with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in patients receiving apomorphine or those with a history of significant QT prolongation unless closely monitored.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT